Qu Biologics is a private clinical stage biopharmaceutical company located in Vancouver, B.C., Canada, which has developed Site Specific Immunomodulators (SSI), a novel class of immunotherapies. www.qubiologics.com
Location: Canada, British Columbia, Burnaby
Employees: 11-50
Phone: +1 604-734-1450
Total raised: $34M
Founded date: 2007
Investors 3
| Date | Name | Website |
| 25.04.2024 | ACA Invest... | acaisg.com |
| - | Harmonix | harmonixfu... |
| - | Curitas Ve... | curitasven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.03.2022 | - | $12M | - |
| 09.12.2020 | - | $8M | - |
| 02.10.2014 | - | $14M | - |
Mentions in press and media 15
| Date | Title | Description |
| 16.12.2024 | Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor | BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immu... |
| 08.06.2024 | Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly | Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to streng... |
| 17.10.2022 | Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly | BURNABY, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immu... |
| 26.09.2022 | Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer | BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune f... |
| 20.07.2022 | Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead | BURNABY, British Columbia, July 20, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore inn... |
| 21.03.2022 | Qu Biologics Closes USD$12M Equity Financing | BURNABY, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore in... |
| 22.07.2021 | HCW Biologics Inc. Completes $56.0 Million Initial Public Offering | Our team is happy to announce that HCW Biologics, a DeepWork Fund II portfolio company, completed an initial public offering (IPO) on 7/20/21. HCW Biologics, a Miramar, FL company, is now trading on the NASDAQ under the ticker “HCWB”. You ... |
| 22.07.2021 | HCW Biologics Inc :. Announces Closing of $56.0 Million Initial Public Offering | MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen h... |
| 20.07.2021 | HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering | MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen h... |
| 23.06.2021 | Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu's First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment | VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore i... |
Show more